No increased mortality from donor or recipient hepatitis B‐ and/or hepatitis C‐positive serostatus after related‐donor allogeneic hematopoietic cell transplantation |
| |
| Authors: | M Tomblyn M Chen M Kukreja MD Aljurf F Al Mohareb BJ Bolwell J‐Y Cahn MH Carabasi RP Gale RE Gress V Gupta GA Hale P Ljungman RT Maziarz J Storek JR Wingard J‐AH Young MM Horowitz KK Ballen |
| |
| Institution: | 1. Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, , Tampa, Florida, USA;2. Center for International Blood and Marrow Transplantation;3. Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, , Milwaukee, Wisconsin, USA;4. Adult Stem Cell Transplantation, King Faisal Specialist Hospital and Research Center, , Riyadh, Saudi Arabia;5. Bone Marrow Transplant, Cleveland Clinic Foundation, , Cleveland, Ohio, USA;6. Service d'Hematologie, H?pital A. Michallon – CHU de Grenoble, , Grenoble, France;7. Hematology/Medical Oncology, Thomas Jefferson University Hospital, , Philadelphia, Pennsylvania, USA;8. Clinical Research, Celgene Corporation, , Summit, New Jersey, USA;9. Experimental Transplantation and Immunology, National Institutes of Health, , Bethesda, Maryland, USA;10. Hematology and Medical Oncology, Princess Margaret Hospital, University of Toronto, , Toronto, Canada;11. Blood and Marrow Transplant Program, All Children's Hospital, , St. Petersburg, Florida, USA;12. Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Karolinska Institutet, , Stockholm, Sweden;13. Bone Marrow Transplant, Center for Hematologic Malignancies, Oregon Health and Science University, , Portland, Oregon, USA;14. Bone Marrow Transplant Program, Tom Baker Cancer Centre, University of Calgary, , Alberta, Canada;15. Bone Marrow Transplant, Medical Hematology/Oncology, Shands Hospital, University of Florida, , Gainesville, Florida, USA;16. Clinical Trials Office, Masonic Cancer Center, University of Minnesota, , Minneapolis, Minnesota, USA;17. Bone Marrow Transplant, Massachusetts General Hospital, , Boston, Massachusetts, USA |
| |
| Abstract: | Limited data exist on allogeneic transplant outcomes in recipients receiving hematopoietic cells from donors with prior or current hepatitis B (HBV) or C virus (HCV) infection (seropositive donors), or for recipients with prior or current HBV or HCV infection (seropositive recipients). Transplant outcomes are reported for 416 recipients from 121 centers, who received a human leukocyte antigen‐identical related‐donor allogeneic transplant for hematologic malignancies between 1995 and 2003. Of these, 33 seronegative recipients received grafts from seropositive donors and 128 recipients were seropositive. The remaining 256 patients served as controls. With comparable median follow‐up (cases, 5.9 years; controls, 6.7 years), the incidence of treatment‐related mortality, survival, graft‐versus‐host disease, and hepatic toxicity, appears similar in all cohorts. The frequencies of hepatic toxicities as well as causes of death between cases and controls were similar. Prior exposure to HBV or HCV in either the donor or the recipient should not be considered an absolute contraindication to transplant. |
| |
| Keywords: | allogeneic transplantation hepatitis B hepatitis C |
|
|
